Poleszczuk J, Luddy K, Chen L et al (2017) Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res 19:75

Article  PubMed Central  PubMed  Google Scholar 

Rubens RD, Sexton S, Tong D, Winter PJ, Knight RK, Hayward JL (1980) Combined chemotherapy and radiotherapy for locally advanced breast cancer. Eur J Cancer 16:351–356

Article  CAS  Google Scholar 

Sims AH, Bartlett JMS (2008) Approaches towards expression profiling the response to treatment. Breast Cancer Res 10:115

Article  PubMed Central  PubMed  Google Scholar 

Selli C, Sims AH (2019F) Neoadjuvant therapy for breast cancer as a model for translational research. Breast Cancer (Auckl) 19(13):1178223419829072. https://doi.org/10.1177/1178223419829072

Article  Google Scholar 

Guarneri V, Broglio K, Kau SW et al (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037–1044

Article  PubMed  Google Scholar 

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164–172. https://doi.org/10.1016/S0140-6736(13)62422-8

Article  PubMed  Google Scholar 

Broglio KR, Quintana M, Foster M et al (2016) Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes. JAMA Oncol 2:751–760

Article  PubMed  Google Scholar 

Food and Drug Administration (2014) HHS Pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval; guidance for industry; availability. Fed Regist 79:60476–60477

Google Scholar 

Esserman LJ, Berry DA, DeMichele A et al (2012) Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL–CALGB 150007/150012, ACRIN 6657. J Clin Oncol 30:3242–3249

Article  PubMed Central  PubMed  Google Scholar 

Colleoni M, Viale G, Zahrieh D et al (2004) Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res 10:6622–6628

Article  CAS  PubMed  Google Scholar 

Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G et al (2015) Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol 26:1280–1291. https://doi.org/10.1093/annonc/mdv161

Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, Evrevin C, Rozette S, Laot L, Lerebours F, Pierga JY, Osdoit M, Faron M, Feron JG, Laé M, Reyal F (2020J 24) Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: validation on a cohort of BC patients treated by neoadjuvant chemotherapy. PLoS ONE 15(6). https://doi.org/10.1371/journal.pone.0234191

Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422. https://doi.org/10.1200/JCO.2007.10.6823

Article  PubMed  Google Scholar 

Masuda N, Lee S-J, Ohtani S, Im Y-H, Lee E-S, Yokota I et al (2017) Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med 376:2147–2159. https://doi.org/10.1056/NEJMoa1612645

von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M et al (2019) Trastuzu- mab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med 380:617–628. https://doi.org/10.1056/NEJMoa1814017

Article  Google Scholar 

Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A et al (2017) Comparison of residual can- cer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181–191. https://doi.org/10.1007/s10549-017-4303-8

Article  PubMed Central  PubMed  Google Scholar 

Cockburn A, Yan J, Rahardja D, Euhus D, Peng Y, Fang Y et al (2014) Modulatory effect of neoadjuvant chemotherapy on biomarkers expression; assessment by digital image analysis and rela- tionship to residual cancer burden in patients with invasive breast cancer. Hum Pathol 45:249–258. https://doi.org/10.1016/j.humpath.2013.09.002

Article  CAS  PubMed  Google Scholar 

Corben AD, Abi-Raad R, Popa I, Teo CHY, Macklin EA, Koerner FC et al (2013) Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemother- apy: a comparison between classifications and their practical application. Arch Pathol Lab Med 137:1074–1082

Article  PubMed  Google Scholar 

Lee SM, Bae SK, Kim TH, Yoon HK, Jung SJ, Park JS et al (2014) Value of 18F-FDG PET/CT for early prediction of pathologic response (by residual cancer burden criteria) of locally advanced breast cancer to neoadjuvant chemotherapy. Clin Nucl Med 39:882–886. https://doi.org/10.1097/RLU.0000000000000531

Article  PubMed  Google Scholar 

Romero A, Garcıa-Saenz JA, Fuentes-Ferrer M, Lopez Garcia-Asenjo JA, Furio ́ V, Roman JM et al (2013) Correlation between response to neoadjuvant chemotherapy and survival in locally advanced breast cancer patients. Ann Oncol 24:655–661. https://doi.org/10.1093/annonc/mds493

Sheri A, Smith IE, Johnston SR, A’Hern R, Nerurkar A, Jones RL et al (2015) Residual prolifer- ative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. Ann Oncol 26:75–80. https://doi.org/10.1093/annonc/mdu508

Article  CAS  PubMed  Google Scholar 

Symmans WF, Wei C, Gould R, Yu X, Zhang Y, Liu M et al (2017) Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer sub- type. J Clin Oncol 35:1049–1060. https://doi.org/10.1200/JCO.2015.63.1010

Article  PubMed Central  CAS  PubMed  Google Scholar 

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685. https://doi.org/10.1158/1078-0432.CCR-04-2421

Article  CAS  PubMed  Google Scholar 

Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G et al (2015) Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIGG. Viale and N. Fusco The Breast 62 (2022) S25eS28 S27 NABCG collaboration. Ann Oncol 26:1280e91

Peintinger F, Sinn B, Hatzis C, Albarracin C, Downs-Kelly E, Morkowski J et al (2015) Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol 28:913–920. https://doi.org/10.1038/modpathol.2015.53

Article  PubMed Central  PubMed  Google Scholar 

Nahleh Z, Sivasubramaniam D, Dhaliwal S, Sundarajan V, Komrokji R (2008) Residual cancer burden in locally advanced breast cancer: a superior tool. Curr Oncol 15(6):271–278. https://doi.org/10.3747/co.v15i6.242

Article  PubMed Central  CAS  PubMed  Google Scholar